Webinar | June 20, 2024

Optimal Formulation Development

Source: Abzena

Formulation plays a pivotal role within the drug development process. Encompassing a spectrum of activities – from developability assessment and buffer optimization to dosage form studies and compatibility testing with administration devices and storage containers – formulation development represents a strategic investment in the early stages. This investment yields significant benefits throughout the development pipeline.

A robust developability program facilitates the identification of potential risks and liabilities associated with a drug candidate's physicochemical properties. By generating critical data on factors like specificity, potency, safety, pharmacokinetics, and manufacturability, such programs contribute to informed decision-making. Early assessment allows for targeted modifications to the drug design, mitigating risks and aligning the candidate with the target product profile (TPP) before incurring the higher costs associated with later-stage development.

View the webinar below to delve into the integration of formulation development within the broader drug development landscape and learn about the importance of de-risking drug candidates through data-driven lead selection processes. Gain valuable insights into the development of a phase-appropriate de-risking strategy that will guide the selection and application of suitable formulation processes to achieve alignment with the optimal target product profile.

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online